Search results
Results From The WOW.Com Content Network
Cefazolin, also known as cefazoline and cephazolin, is a first-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [2] Specifically it is used to treat cellulitis , urinary tract infections , pneumonia , endocarditis , joint infection , and biliary tract infections . [ 2 ]
Specifically, a small amount of evidence supports the use of intravenous cefazolin once rather than three times a day when it is combined with probenecid. [ 2 ] It has also found use as a masking agent , [ 3 ] potentially helping athletes using performance-enhancing substances to avoid detection by drug tests.
In pharmacokinetics, the rate of infusion (or dosing rate) refers not just to the rate at which a drug is administered, but the desired rate at which a drug should be administered to achieve a steady state of a fixed dose which has been demonstrated to be therapeutically effective. Abbreviations include K in, [1] K 0, [2] or R 0.
The contraindication, however, should be viewed in the light of recent epidemiological work suggesting, for many second-generation (or later) cephalosporins, the cross-reactivity rate with penicillin is much lower, having no significantly increased risk of reactivity over the first generation based on the studies examined.
Cefapirin (INN, also spelled cephapirin) is an injectable, first-generation cephalosporin antibiotic.It is marketed under the trade name Cefadyl. Production for use in humans has been discontinued in the United States.
It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth. [5] Cefalexin can treat certain bacterial infections, including those of the middle ear, bone and joint, skin, and urinary tract. [4] It may also be used for certain types of pneumonia and strep throat and to prevent bacterial ...
The overall discontinuation rate for ceftaroline-treated subjects was 2.7% compared to a rate of 3.7% for the comparator group-treated subjects. The most common adverse reactions occurring in > 2% of subjects receiving ceftaroline in the pooled phase-III clinical trials were diarrhea, nausea, and rash.: [18]
The primary measurement of efficacy were clinical cure rates at test-of-cure visit, which occurred 7-14 days after end-of-treatment. [15] Of the participants who received ceftobiprole medocaril, 76.4% achieved clinical cure compared to 79.3% of participants who received the comparator. [15]